The scale of the problem is sobering. Lower respiratory infections consistently rank among the leading causes of infectious mortality worldwide, and the latest Global Burden of Disease analyses confirm that the burden has not meaningfully receded. Without prompt treatment, bacterial pneumonia can trigger acute inflammatory cascades that spiral into sepsis and multi-organ failure. Standard antibiotic therapy, meanwhile, is being undermined from two directions at once: the rise of multidrug-resistant pathogens such as carbapenem-resistant Enterobacteriaceae, methicillin-resistant Staphylococcus aureus, and resistant strains of Pseudomonas aeruginosa and Klebsiella pneumoniae, and the sheer difficulty of getting drugs to the site of infection inside the lung.

That second problem is less famous but just as consequential. The lung is a fortress of physiological barriers designed to keep foreign particles out. Inhaled or systemically delivered antibiotics must contend with viscoelastic mucus layers, pulmonary surfactants, an acidic microenvironment at sites of infection, oxidative stress from reactive oxygen species, and hypertonic waste accumulation. Each of these can degrade, trap, or deactivate drug molecules before they ever reach bacteria embedded in alveoli or hiding inside biofilms. The review emphasizes that these barriers are not merely passive obstacles; they actively shape the pharmacokinetics of inhaled and intravenous therapies, which is why so many promising antibiotics underperform in the clinic.

Nanotechnology enters the picture as a way to turn these barriers from liabilities into triggers. Nanocarriers, typically particles ranging from tens to a few hundred nanometers, can be engineered to protect their cargo during transit, penetrate mucus, and release their payload only when specific conditions are met. The review categorizes the main platforms into inorganic systems, polymeric nanoparticles, extracellular vesicle-based carriers, and hybrid nanoplatforms, each with distinct strengths. Inorganic materials such as gold and silver nanoparticles, mesoporous silica, and metal-organic frameworks offer tunable surfaces and, in some cases, intrinsic antimicrobial activity. Silver nanoparticles, for example, generate reactive oxygen species that damage bacterial membranes, while metal-organic frameworks can act as catalytic nanoreactors that deplete bacterial antioxidant defenses such as glutathione.

Polymeric carriers, including particles made of poly(lactide-co-glycolide) and chitosan, have proven particularly valuable for pulmonary delivery because they can be formulated into inhalable dry powders and engineered for mucoadhesion or mucus penetration. One highlighted strategy uses muco-adhesive chitosan-coated polyphenol nanoparticles to sustain the pulmonary delivery of polymyxin B, a last-resort antibiotic whose systemic use is limited by nephrotoxicity. Localizing such drugs directly to infected lung tissue with nanoparticles could preserve antibacterial potency while sparing the kidneys, and studies cited in the review suggest that precise delivery to the lung infection microenvironment also reduces collateral damage to the gut microbiome, a common and underappreciated side effect of systemic antibiotics.

Perhaps the most technically elegant section of the review concerns stimuli-responsive targeting. Rather than releasing drugs continuously, these nanocarriers exploit the distinctive chemistry of infected lungs as a built-in switch. pH-sensitive systems discharge their cargo in the acidic microenvironment surrounding bacterial colonies. Reactive-oxygen-species-responsive polymers disintegrate amid the oxidative burst of inflamed tissue. Enzyme-responsive designs release antimicrobial peptides only when bacterial proteases or beta-lactamases cleave their protective shells, a strategy that also helps neutralize resistance enzymes. External triggers add another layer of control: ultrasound-activated nanoantibiotics have been shown to mediate sequential therapy against MRSA lung infections, while magnetothermal and piezoelectric sonodynamic platforms generate localized antibacterial effects in inhaled formulations. Light-responsive systems, long explored in oncology, are now being adapted for antimicrobial phototherapy of the airways.

Targeting itself comes in three flavors, the review explains. Passive targeting exploits the enhanced permeability and retention effect, in which nanoparticles accumulate at inflamed, leaky tissue. Active targeting decorates particle surfaces with ligands, such as mannose or hyaluronic acid, that bind receptors on infected cells or bacterial surfaces. Biomimetic targeting goes further still: nanoparticles cloaked in neutrophil or macrophage membranes inherit the natural homing behavior of immune cells and can even recognize bacteria directly. Neutrophil membrane-coated nanoparticles have shown enhanced antimicrobial activity against resistant K. pneumoniae, and homotypic-recognizing nanovesicles have been engineered to hunt intracellular bacteria. In one striking example from the broader literature, nanoparticle-modified microrobots have delivered antibiotics in vivo to treat acute bacterial pneumonia, hinting at a future where active propulsion complements passive circulation.

Beyond killing bacteria, the review devotes substantial attention to immune modulation, reflecting a growing recognition that pneumonia mortality often stems from the host’s own inflammatory response as much as from the pathogen itself. Nanocarriers can deliver anti-inflammatory agents such as the IKK inhibitor TPCA-1 via platelet-derived extracellular vesicles to calm cytokine storms, or dexamethasone directly to alveolar macrophages to reshape the immune microenvironment. Extracellular vesicles derived from mesenchymal stromal cells have demonstrated therapeutic effects in severe pneumonia models, and tracheal epithelial cell exosomes carrying microRNA-21-5p have been shown to inhibit macrophage pyroptosis, a fiery form of cell death that fuels lung inflammation. Nanovaccines represent the preventive frontier: manganese-based nanoparticle vaccines, outer membrane vesicle coatings, and multiepitope chitosan-PLGA formulations against Acinetobacter baumannii all illustrate how nanoscale engineering can train immunity against the most dangerous respiratory pathogens.

Gene therapy rounds out the therapeutic arsenal. Lipid nanoparticles, the same platform technology behind mRNA vaccines, are being loaded with siRNA and delivered by nebulization to silence bacterial virulence factors in Staphylococcus aureus pneumonia, while CRISPR-Cas systems packaged in nanocarriers have been used to cure plasmids carrying carbapenemase genes from resistant bacteria. Antimicrobial peptide-derived lipid nanoparticles enabling lung-targeted mRNA therapy for multidrug-resistant pneumonia point toward a modality in which the lung itself is instructed to produce therapeutic proteins on site. Combined with in situ CAR-macrophage engineering demonstrated in sepsis models, these approaches suggest that nanomedicine may eventually treat pneumonia not by delivering a drug, but by reprogramming the host’s cellular machinery.

The authors are candid about the obstacles between laboratory promise and bedside reality. Carrier heterogeneity makes batch-to-batch consistency difficult, particularly for biologically derived extracellular vesicles. Pulmonary-specific barriers demand formulation strategies that differ fundamentally from those used in cancer nanomedicine, and the toxicity of inhaled metal nanoparticles remains an open question requiring careful biokinetic study. Clinical scalability, regulatory pathways, and the cost of manufacturing complex biomimetic systems all loom large. Yet the trajectory is clear: liposomal ciprofloxacin has already completed phase 3 trials for chronic Pseudomonas lung infections, and nebulized liposomal amikacin has advanced through phase 2 studies in cystic fibrosis patients, proving that inhaled nanotherapeutics can navigate clinical development. The review’s expert opinion is that the convergence of targeted, stimuli-responsive, and immune-modulating nanocarriers offers a genuine pathway to precision therapy for bacterial pneumonia, a disease that has waited far too long for its nanotechnology moment.

Subject of Research: Nanotherapeutic drug delivery systems for the targeted and precision treatment of bacterial pneumonia

Article Title: Nanotherapeutic delivery systems in bacterial pneumonia: targeting, responsiveness, and immune modulation toward precision therapy

Article References: Krishnamoorthi, R., Wang, Y.-T., Lin, C.-Y., Alalaiwe, A., & Fang, J.-Y. (2026). Nanotherapeutic delivery systems in bacterial pneumonia: targeting, responsiveness, and immune modulation toward precision therapy. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00829-y

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00829-y

Keywords: bacterial pneumonia, nanocarriers, drug delivery, antimicrobial resistance, stimuli-responsive nanoparticles, extracellular vesicles, immunomodulation, pulmonary drug delivery, antimicrobial peptides, nanovaccines, lipid nanoparticles, metal-organic frameworks